BBHC
AXSM icon

Brown Brothers Harriman & Co’s Axsome Therapeutics AXSM Stock Holding History

Brown Brothers Harriman & Co’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.5K Buy
62
+8
+15% +$1.38K ﹤0.01% 1347
2025
Q4 		$9.86K Buy
+54
New +$7.54K ﹤0.01% 1345

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Brothers Harriman & Co's AXSM Position: Q1 2026 in Review

Brown Brothers Harriman & Co increased its Axsome Therapeutics (AXSM) stake by 15% in Q1 2026, buying an estimated $1.38K and bringing the position to 62 shares worth $10.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1347.

Brown Brothers Harriman & Co first reported a position in AXSM in Q4 2025 and has held it in 2 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Brown Brothers Harriman & Co held 62 shares of Axsome Therapeutics worth $10.5K as of Q1 2026.
  • Brown Brothers Harriman & Co bought 8 Axsome Therapeutics shares in Q1 2026, an estimated $1.38K.
  • Axsome Therapeutics made up ﹤0.01% of Brown Brothers Harriman & Co's portfolio in Q1 2026, its #1347 holding.
  • Brown Brothers Harriman & Co first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2026, filed 14 May 2026.